These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 710488)

  • 1. Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemia.
    Wampler GL; Regelson W; Bardos TJ
    Eur J Cancer (1965); 1978 Sep; 14(9):977-82. PubMed ID: 710488
    [No Abstract]   [Full Text] [Related]  

  • 2. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of resistance and therapeutic synergism among alkylating agents.
    Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
    Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the biochemical pharmacology of selected alkylating agents.
    Wheeler GP
    Transplant Proc; 1973 Sep; 5(3):1167-70. PubMed ID: 4738047
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutagenic and chemotherapeutic activity in L1210 leukemia of several monofunctional alkylating agents.
    Schmid FA; Otter GM; Mehta BM
    Cancer Res; 1985 Jan; 45(1):40-4. PubMed ID: 3965147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of chemical agents against the plasma cell tumor LPC-1 in mice.
    Abraham D; Carbone PP; Venditti JM; Kline I; Goldin A
    Biochem Pharmacol; 1967 Apr; 16(4):665-73. PubMed ID: 6033787
    [No Abstract]   [Full Text] [Related]  

  • 7. Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.
    Takamizawa A; Matsumoto S; Iwata T; Tochino Y; Katagiri K
    J Med Chem; 1974 Nov; 17(11):1237-9. PubMed ID: 4416021
    [No Abstract]   [Full Text] [Related]  

  • 8. Some novel potential alkylating agents derived from diethylstilbestrol.
    Roushdi IM; Omar AM; Ragab MS; Awad M
    J Med Chem; 1976 Nov; 19(11):1333-6. PubMed ID: 1003412
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
    Stoychkov JN; Milushev AS; Todorov DK
    Neoplasma; 1980; 27(1):33-6. PubMed ID: 6892839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
    Takamizawa A; Matsumoto S; Iwata T; Makino I; Yamaguchi K; Uchida N; Kasai H; Shiratori O; Takase S
    J Med Chem; 1978 Feb; 21(2):208-14. PubMed ID: 621716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of current alkylating agents with a homo-aza-steroidal ester for antineoplastic activity.
    Catsoulacos P; Papageorgiou A; Margarity E; Mourelatos D; Mioglou E
    Oncology; 1994; 51(1):74-8. PubMed ID: 8265107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal potentiation of the antitumor activity of alkylating drugs.
    Rutman RJ; Ritter CA; Avadhani NG; Hansel J
    Cancer Treat Rep; 1976 May; 60(5):617-8. PubMed ID: 991151
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems.
    Wall ME; Abernethy GS; Carroll FI; Taylor DJ
    J Med Chem; 1969 Sep; 12(5):810-8. PubMed ID: 5812193
    [No Abstract]   [Full Text] [Related]  

  • 14. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.
    Institóris E; Szikla K; Otvös L; Gál F
    Cancer Chemother Pharmacol; 1989; 24(5):311-3. PubMed ID: 2758560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutagenic and chemotherapeutic activity in L1210 leukemia of several monofunctional alkylating agents.
    Wheeler GP; Adamson DJ; Webster J
    Cancer Res; 1985 Jul; 45(7):3400-2. PubMed ID: 4005864
    [No Abstract]   [Full Text] [Related]  

  • 16. Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines.
    Sladek NE; Low JE; Landkamer GJ
    Cancer Res; 1985 Feb; 45(2):625-9. PubMed ID: 3967238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and response to certain cancer chemotherapeutic agents of an acute lymphocytic leukemia arising in a BALB-c times DBA-2F1 mouse.
    Yancey ST; Bleyer WA
    Cancer Res; 1974 Aug; 34(8):1866-9. PubMed ID: 4526157
    [No Abstract]   [Full Text] [Related]  

  • 18. L1210 leukemia hybrids isolated after fusion of alkylating agent-resistant sublines.
    Schmid FA; Otter GM; Hirano I
    Leuk Res; 1988; 12(1):67-70. PubMed ID: 3357349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the antitumor effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and cyclophosphamide by vitamin A.
    Cohen MH; Carbone PP
    J Natl Cancer Inst; 1972 Apr; 48(4):921-6. PubMed ID: 5023689
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.